{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-003545","form_type":"8-K","ticker":null,"cik":"0001831874","company_name":"Iris Acquisition Corp","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.151860+00:00","generated_at":"2026-05-28T01:18:56.774191+00:00","sec_items":["4.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Iris Acquisition Corp restates Q2 and Q3 2024 financials over undisclosed related party loan","bullets":["Determined unaudited financials for June 30, 2024 and Sept 30, 2024 should no longer be relied upon.","A $1.216M loan from Hana Immunotherapeutics (affiliate of Liminatus Pharma CEO) to fund sponsor managing member acquisition was omitted.","Loan was a material related party transaction that required disclosure; Audit Committee discussed with auditor Marcum LLP.","Loan settled on Dec 29, 2024 via delivery of shares in a private Korean company.","Former managing member Columbass resigned Oct 30, 2024; Iris Equity Holdings appointed as managing member."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-003545","json":"https://secwatch.observer/filing/0001104659-25-003545.json","markdown":"https://secwatch.observer/filing/0001104659-25-003545.md","text":"https://secwatch.observer/filing/0001104659-25-003545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/0001104659-25-003545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/tm253036d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:18:56.774191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e15dd60e7d345428dd1a888aeba60ee3ba07fbaf","claim":"Iris Acquisition Corp reported that prior financial statements should not be relied upon.","evidence_excerpt":"determined that the unaudited financial statements for the quarters ended June 30, 2024 and September 30, 2024 should no longer be relied upon.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831874/000110465925003545/0001104659-25-003545-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"},{"label":"Auditor","value":"Marcum LLP"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}